Business
Axon Therapies Raises $32M in Oversubscribed Series A to Transform Heart Failure Treatment
Axon Therapies, a clinical-stage medical device company pioneering a new approach to treating heart failure, today announced the close of an oversubscribed $32 million Series A financing. The round was co-led by new investors Earlybird Venture Capital and Santé Ventures, with participation by existing investor Deerfield Management and new investors CD Capital and KOFA Healthcare.
About this update from Axon Enterprise, Inc.
[{"type":"text","content":"Funding supports clinical trials of a minimally invasive therapy targeting a root cause of heart failure; co-founder Zoar Engelman, PhD, appointed CEO","length":150,"tagName":"p"},{"type":"text","content":"NEW YORK, Sept. 25, 2025 /PRNewswire/ -- Axon Therapies, a clinical-stage medical device company pioneering a new approach to treating heart failure, today announced the close of an oversubscribed $32 million Series A financing. The round was co-led by new investors Earlybird Venture Capital and Santé Ventures, with participation by existing investor Deerfield Management and new investors CD Capital and KOFA Healthcare.","length":423,"tagName":"p"},{"type":"image","alt":"Co-founder Zoar Engelman, PhD, appointed CEO of Axon Therapies","displaySize":"","headline":null,"caption":"Co-founder Zoar Engelman, PhD, appointed CEO of Axon Therapies","className":"","disableSlideshowImg":false,"size":{"original":{"width":302,"height":400,"url":"https://media.zenfs.com/en/prnewswire.com/086d66c51785f37ffad3f90fb8ccc3ec"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/A4f2F4Ppk7hsN9fhI6RRnw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTU1NjtjZj13ZWJw/https://media.zenfs.com/en/prnewswire.com/086d66c51785f37ffad3f90fb8ccc3ec","width":302,"height":400}},"href":"https://mma.prnewswire.com/media/2782398/Axon_Zoar_Engelman.html","hrefExternal":true,"rel":"nofollow"},{"type":"text","content":"The financing will accelerate Axon's next phase of clinical development, including two double-blinded randomized feasibility studies in heart failure – a condition that affects millions of people worldwide with limited treatment options. The first is a confirmatory study for its novel splanchnic ablation therapy in patients with Heart Failure with Preserved Ejection Fraction (HFpEF). The second is a multiple-center study of splanchnic ablation in Failure with Reduced Ejection Fraction (HFrEF).","length":502,"tagName":"p"},{"type":"text","content":"In conjunction with the financing, the company announced that Zoar Engelman, PhD, Axon's co-founder and former Chief Scientific Officer, has been appointed Chief Executive Officer.","length":184,"tagName":"p"},{"type":"text","content":""Heart failure is one of the leading causes of hospitalization and death worldwide, yet patients still face a lack of effective treatment options," said Dr. Engelman, CE...